The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of epacadostat with pembrolizumab in metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma requiring paired biopsies.
 
Adel Kardosh
No Relationships to Disclose
 
Diane Tseng
Patents, Royalties, Other Intellectual Property - Use of Anti-CD47 Agents to Enhance Immunization. Provisional Application to U.S. Patent and Trademark Office. Application Number 61817229
 
Bita Sahaf
No Relationships to Disclose
 
Ativ Zomet
No Relationships to Disclose
 
Julia Krupa
No Relationships to Disclose
 
George A. Fisher
Stock and Other Ownership Interests - Seagen (I)
Honoraria - Merck, Genentech, Ipsen
Consulting or Advisory Role - Celgene; ipsen
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); EpicentRx (Inst); Forty seven (Inst); Genentech/Roche (Inst); Ipsen (Inst); Merck (Inst); Newlink Genetics (Inst); Pharmaceutical Research Associates (Inst); Polaris (Inst); Sun Pharma (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Merck
 
David S Wang
No Relationships to Disclose
 
Crystal Mackall
No Relationships to Disclose
 
Pamela L. Kunz
Stock and Other Ownership Interests - Guardant Health
Consulting or Advisory Role - Ipsen; Lexicon; Novartis
Research Funding - Advanced Accelerator Applications (Inst); Dicerna (Inst); Esanex (Inst); Genentech/Roche (Inst); Ipsen (Inst); Lexicon (Inst); Merck (Inst); Oxigene (Inst)